Valiant Organics to start production of OAP and Pharma Intermediates

Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23

Rossari Biotech Q1 FY23 revenue up 88%; Profit up 17%

Profit after Tax (PAT) was up 18% for Q1 FY23 to reach Rs. 28.7 crore whereas EBITDA was up 52% to reach Rs. 57.7 crore

Thermo Fisher to expand dry powder media manufacturing facility in New York

With this expansion, the Grand Island site provides redundant capacity to support global supply of media and further extends the site’s capabilities to produce the high-quality technology and materials needed for the development and commercial manufacturing of vaccines and biologic therapies

LYNPARZA approved in the EU as adjuvant treatment for early breast cancer

First and only PARP inhibitor to improve invasive disease-free survival, the primary endpoint, and overall survival, a key secondary endpoint, in these patients

Lupin Q1 FY23 consolidated loss drops to Rs. 89.08 Cr

Lupin is the 6th largest company in the Indian Pharmaceutical Market

Zydus receives final approval from the USFDA for Ivermectin Cream

Ivermectin Cream is a used for the treatment of inflammatory lesions of rosacea.

Merck KGaA posts higher earnings, profits across business segments

Despite the price increases for raw materials and logistics, EBITDA pre rose organically by 3.2% to € 1,782 million

Creoptix launches new WAVEcontrol to deliver automated and label-free analysis for biologics drug-discovery

The WAVEsystem with the WAVEcontrol 4.0 embedded

Merck and Eisai provide update on Phase 3 LEAP-002 trial evaluating KEYTRUDA

The safety profile of KEYTRUDA plus LENVIMA was consistent with previously reported data on the combination.

PIB: Quality control of Ayush drugs